Literature DB >> 17373153

Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept.

Robert L Henderson1.   

Abstract

We present a case where etanercept--a soluble tumor necrosis factor receptor-Fc fusion protein-was safe and effective in treating the painful skin lesions of a 24-year-old patient with hidradenitis suppurativa, resulting in an improvement in quality of life.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17373153

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  2 in total

1.  Hidradenitis Suppurativa or Hidradenitis Suppurativa-Like Lesions Located on Amputation Stumps? Description of 2 Cases.

Authors:  Nicolas Kluger; Philippe Guillem; Minttu Kivivuori; Kirsi Isoherranen
Journal:  Skin Appendage Disord       Date:  2019-10-10

2.  A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.

Authors:  Robert A Lee; Erica Dommasch; James Treat; Joslyn Sciacca-Kirby; Samuel Chachkin; Jennifer Williams; Daniel B Shin; James J Leyden; Carmela Vittorio; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2009-01-31       Impact factor: 11.527

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.